Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Akzo Nobel NV

www.akzonobel.com

Latest From Akzo Nobel NV

Appointments: Lilly, Kiadis, Pliant, Alma, NeuroVia and Nektar Therapeutics

This week's roundup includes a handful of promotions by Eli Lilly, and various board and high-level appointments by companies including Kiadis Pharma, Aeterna Zentaris, Dermavant Sciences and Pliant Therapeutics.

Appointments BioPharmaceutical

FDA Sending More Drug GMP Warning Letters to Foreign Sites

FDA warning letters are up at foreign sites and down at domestic sites as agency ramps up presence abroad. Inadequate OOS investigations and faulty testing of drug components were top violations; contamination was a common issue; firms cited included Novartis, Mylan, Smithkline Beecham, Lonza and Noven.

BioPharmaceutical Regulation

The Abbott Split Up: Who Wins?

After implementing a major workforce reduction in January, Abbott Laboratories re-organized its diversified company into three units – proprietary pharmaceuticals, durable growth products and innovation-driven devices. Its latest announcement cements that change: Abbott will divide into a diversified medical products company.

Medical Device BioPharmaceutical

Defining Biopharma Dealmaking Success: An Analysis Of 2003 Alliances

This article examines the question do external biopharma programs succeed at similar rates as internal projects? IN VIVO examined this question by analyzing the alliances of 2003, mining both Elsevier's Strategic Transactions database and SEC documents, and bolstering these data with independent reporting.
Research and Development Strategies
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register